NASDAQ:DBVT - DBV TECHNOLOGIE/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DBV TECHNOLOGIE/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.09 -0.51 (-4.40 %) (As of 01/27/2020 01:01 AM ET) Add Compare Today's Range$10.96Now: $11.09▼$11.7650-Day Range$7.80MA: $10.63▼$12.9852-Week Range$6.08Now: $11.09▼$13.49Volume268,295 shsAverage Volume418,210 shsMarket Capitalization$1.01 billionP/E RatioN/ADividend YieldN/ABeta1.91 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DBVT Previous Symbol CUSIPN/A CIK1613780 Webhttp://www.dbv-technologies.com/ Phone33-1-55-42-78-78Debt Debt-to-Equity Ratio0.19 Current Ratio3.00 Quick Ratio2.96Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$17.17 million Price / Sales58.96 Cash FlowN/A Price / Cash FlowN/A Book Value$2.41 per share Price / Book4.60Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees244 Outstanding Shares91,280,000Market Cap$1.01 billion Next Earnings Date4/6/2020 (Estimated) OptionableOptionable Receive DBVT News and Ratings via Email Sign-up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:DBVT Rates by TradingView DBV TECHNOLOGIE/S (NASDAQ:DBVT) Frequently Asked Questions What is DBV TECHNOLOGIE/S's stock symbol? DBV TECHNOLOGIE/S trades on the NASDAQ under the ticker symbol "DBVT." How were DBV TECHNOLOGIE/S's earnings last quarter? DBV TECHNOLOGIE/S (NASDAQ:DBVT) released its quarterly earnings results on Thursday, March, 26th. The company reported ($0.79) EPS for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.35. View DBV TECHNOLOGIE/S's Earnings History. When is DBV TECHNOLOGIE/S's next earnings date? DBV TECHNOLOGIE/S is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for DBV TECHNOLOGIE/S. What price target have analysts set for DBVT? 6 brokerages have issued 1 year price objectives for DBV TECHNOLOGIE/S's stock. Their forecasts range from $14.00 to $25.00. On average, they anticipate DBV TECHNOLOGIE/S's stock price to reach $18.20 in the next year. This suggests a possible upside of 64.1% from the stock's current price. View Analyst Price Targets for DBV TECHNOLOGIE/S. What is the consensus analysts' recommendation for DBV TECHNOLOGIE/S? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV TECHNOLOGIE/S in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DBV TECHNOLOGIE/S. Has DBV TECHNOLOGIE/S been receiving favorable news coverage? News headlines about DBVT stock have been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. DBV TECHNOLOGIE/S earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for DBV TECHNOLOGIE/S. Who are some of DBV TECHNOLOGIE/S's key competitors? Some companies that are related to DBV TECHNOLOGIE/S include Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC), Regenxbio (RGNX), Cortexyme (CRTX) and SpringWorks Therapeutics (SWTX). What other stocks do shareholders of DBV TECHNOLOGIE/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other DBV TECHNOLOGIE/S investors own include Aimmune Therapeutics (AIMT), Bellicum Pharmaceuticals (BLCM), Immunomedics (IMMU), Aldeyra Therapeutics (ALDX), Exelixis (EXEL), Fate Therapeutics (FATE), Pieris Pharmaceuticals (PIRS), Celldex Therapeutics (CLDX), Five Prime Therapeutics (FPRX) and Heron Therapeutics (HRTX). Who are DBV TECHNOLOGIE/S's key executives? DBV TECHNOLOGIE/S's management team includes the folowing people: Dr. Pierre-Henri Benhamou, Co-Founder & Non-Exec. Chairman (Age 64)Mr. David Schilansky, Deputy CEO & CFO (Age 44)Dr. Laurent Martin, Chief Devel. Officer (Age 52)Mr. Daniel Tassé, CEO & Director (Age 59)Mr. Bertrand Dupont, Co-Founder & CTO (Age 67) Who are DBV TECHNOLOGIE/S's major shareholders? DBV TECHNOLOGIE/S's stock is owned by a variety of of institutional and retail investors. Top institutional investors include First Midwest Bank Trust Division (0.64%), Syquant Capital Sas (0.47%) and Premier Asset Management LLC (0.07%). Which major investors are selling DBV TECHNOLOGIE/S stock? DBVT stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division. Which major investors are buying DBV TECHNOLOGIE/S stock? DBVT stock was acquired by a variety of institutional investors in the last quarter, including Syquant Capital Sas and Premier Asset Management LLC. How do I buy shares of DBV TECHNOLOGIE/S? Shares of DBVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is DBV TECHNOLOGIE/S's stock price today? One share of DBVT stock can currently be purchased for approximately $11.09. How big of a company is DBV TECHNOLOGIE/S? DBV TECHNOLOGIE/S has a market capitalization of $1.01 billion and generates $17.17 million in revenue each year. The company earns $-196,140,000.00 in net income (profit) each year or ($3.39) on an earnings per share basis. DBV TECHNOLOGIE/S employs 244 workers across the globe.View Additional Information About DBV TECHNOLOGIE/S. What is DBV TECHNOLOGIE/S's official website? The official website for DBV TECHNOLOGIE/S is http://www.dbv-technologies.com/. How can I contact DBV TECHNOLOGIE/S? DBV TECHNOLOGIE/S's mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The company can be reached via phone at 33-1-55-42-78-78 or via email at [email protected] MarketBeat Community Rating for DBV TECHNOLOGIE/S (NASDAQ DBVT)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 344 (Vote Outperform)Underperform Votes: 365 (Vote Underperform)Total Votes: 709MarketBeat's community ratings are surveys of what our community members think about DBV TECHNOLOGIE/S and other stocks. Vote "Outperform" if you believe DBVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DBVT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: What is a death cross?
